Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type
Early-stage|Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
DRUG: Anti-PD-1 monoclonal antibody
Rate of Complete response after inductive therapy, complete resolution of disease in imaging and biopsy after inductive therapy, 2-4 weeks after inductive anti-PD-1 antibody
Progression-free survival rate at year 2 after enrollment, 2y-PFS, From enrollment to any disease progression or death, 2-year|Overall Survival rate at year 2/5 after enrollmentï¼Œ2y-/5y-OS, From enrollment to death, 2-year, 5-year|Rate of acute toxicity (any and above grade 3), toxicities according to CTCAE criteria, From enrollment to 3 months after treatment|Quality of Life change, QoL, measurement basing on EORTC-QLQ-HN35 tables, baseline, 1/3/6/12/24 months after treatment|Quality of Life change, QoL, measurement basing on EORTC-QLQ-C30 tables, baseline, 1/3/6/12/24 months after treatment
Biomarkers to predict anti-PD-1 antibody efficacy and 2y-PFS, potential biomarkers in baseline tumor samples and blood samples, baseline
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type